GenSight Biologics SA (SIGHT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

GenSight Biologics SA (SIGHT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH470860D
  • |
  • Pages: 49
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

GenSight Biologics SA (GenSight) is a clinical stage biotechnology company that discovers and develops novel therapies for mitochondrial and neurodegenerative diseases. The company's product pipeline comprises GS010 and GS030, developed for the treatment of retinal degenerative diseases. It develops solutions for preserving or restoring vision in patients suffering from very low vision or blindness due to degenerative retinal and inherited ophthalmologic diseases. GenSight's drugs target against gene replacement therapy for vision loss in leber hereditary optic neuropathy. It also develops products for retinitis pigmentosa and other hereditary diseases of retina. GenSight is headquartered in Paris, France.

GenSight Biologics SA (SIGHT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents

List of Tables

List of Figures

GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

GenSight Biologics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

GenSight Biologics SA, Medical Devices Deals, 2012 to YTD 2018

GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

GenSight Biologics SA, Pharmaceuticals & Healthcare, Deal Details

Venture Financing

GenSight Biologics Raises USD41.6 Million In Series A Financing

Partnerships

GenSight Biologics Enters into Research Agreement with Pierre and Marie Curie University, INSERM and CNRS

GenSight Biologics Enters into Research Agreement with UPMC, INSERM and CNRS

GenSight Biologics Enters into Research Agreement with Friedrich Miescher Institute

GenSight Biologics Enters into Agreement with Genethon

Licensing Agreements

GenSight Biologics Enters into Licensing Agreement with Inserm Transfert

Gensight Biologics Enters into Option Agreement with Massachusetts Institute of Technology

GenSight Biologics Enters into Licensing Agreement with Avalanche Biotech

GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert

GenSight Biologics Enters into Licensing Agreement with Novartis Pharma

Equity Offering

Gensight Biologics Raises USD25 Million in Private Placement of Shares

GenSight Biologics Announces Underwriters Exercise of Partial Over-Allotment Option for IPO of Shares for USD50.5 Million

GenSight Biologics Raises USD36 Million in Private Placement of Series B Preferred Stock

GenSight Biologics SA-Key Competitors

GenSight Biologics SA-Key Employees

GenSight Biologics SA-Locations And Subsidiaries

Head Office

Recent Developments

Financial Announcements

Jan 25, 2018: GenSight Biologics Reports �55 Million 2017 Year-End Cash Position and Provides Corporate Update

Jul 28, 2017: GenSight Biologics Reports Interim Financial Results for the First Half of 2017

Apr 26, 2017: GenSight Biologics Reports Its Cash Position as of March 31, 2017

Mar 13, 2017: GenSight Biologics Reports Full Year 2016 Financial Results

Corporate Communications

Oct 25, 2017: GenSight Biologics Appoints Barrett Katz as Chief Medical Officer

Oct 02, 2017: GenSight Biologics Integrates the Enternext PEA-PME 150 Index

May 03, 2017: Gensight Biologics Appoints Mohamed Genead as Chief Medical Officer

Product News

10/16/2017: GenSight Biologics to Present Data on GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy

06/14/2017: GenSight Biologics Reports Long-Term Positive Safety and Visual Acuity Results at Week 96 in Phase I/II Study of GS010 for the Treatment of Leber's Hereditary Optic Neuropathy

05/08/2017: GenSight Biologics to Present Data on GS030 at the Annual Meeting of ARVO

Product Approvals

Jan 31, 2017: GenSight Biologics Receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa

Clinical Trials

Aug 01, 2017: GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the Treatment of Leber's Hereditary Optic Neuropathy

May 08, 2017: GenSight Biologics to Present Data on GS010 at the Annual Meeting of ARVO

Feb 21, 2017: GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber's Hereditary Optic Neuropathy

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer

List of Figures

GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018

GenSight Biologics SA, Medical Devices Deals, 2012 to YTD 2018

List of Tables

GenSight Biologics SA, Pharmaceuticals & Healthcare, Key Facts, 2016

GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018

GenSight Biologics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018

GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018

GenSight Biologics SA, Deals By Therapy Area, 2012 to YTD 2018

GenSight Biologics SA, Medical Devices Deals, 2012 to YTD 2018

GenSight Biologics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018

GenSight Biologics Raises USD41.6 Million In Series A Financing

GenSight Biologics Enters into Research Agreement with Pierre and Marie Curie University, INSERM and CNRS

GenSight Biologics Enters into Research Agreement with UPMC, INSERM and CNRS

GenSight Biologics Enters into Research Agreement with Friedrich Miescher Institute

GenSight Biologics Enters into Agreement with Genethon

GenSight Biologics Enters into Licensing Agreement with Inserm Transfert

Gensight Biologics Enters into Option Agreement with Massachusetts Institute of Technology

GenSight Biologics Enters into Licensing Agreement with Avalanche Biotech

GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert

GenSight Biologics Enters into Licensing Agreement with Novartis Pharma

Gensight Biologics Raises USD25 Million in Private Placement of Shares

GenSight Biologics Announces Underwriters Exercise of Partial Over-Allotment Option for IPO of Shares for USD50.5 Million

GenSight Biologics Raises USD36 Million in Private Placement of Series B Preferred Stock

GenSight Biologics SA, Key Competitors

GenSight Biologics SA, Key Employees

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

select a license

Single User License
USD 250 INR 16608
Site License
USD 500 INR 33215
Corporate User License
USD 750 INR 49823

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com